Sonova “outperforming” the market – strong FY 2025/26 results announced

Sonova has lauded a notably strong set of FY 2025/26 annual results, reporting 5.9% local-currency sales growth and a 17.3% rise in normalised operating profit. For the 2026/27 financial year, “Sonova expects consolidated sales growth of 5-8% and core EBIT growth of 7-10%, both at constant exchange rates, reflecting confidence in the renewed strategy, the strong product pipeline, continued profitable growth, and...

No actionable change — this is a corporate financial report with no direct clinical implications.

Sonova's strong performance signals continued investment capacity in hearing technology R&D and market expansion, which may shape product availability and pricing across the audiology sector.

1. 01Sonova reported 5.9% local-currency sales growth for FY 2025/26.
2. 02Normalised operating profit rose 17.3% year-over-year.
3. 03FY 2026/27 guidance: 5–8% consolidated sales growth and 7–10% core EBIT growth.
4. 04Results described as 'outperforming' the broader hearing health market.
5. 05Strong financials suggest Sonova is well-positioned to sustain R&D and market investment.